Tag:

R&D

Latest Headlines

Latest Headlines

Virtual Finger provides faster, better way to study 3D images

The tool will allow users to sift through three-dimensional images, such as synapses or neurons, more efficiently and comprehensively than previous technology allowed.

PEDv diagnostic hits market as vets predict 2.5 million more deaths

With the porcine epidemic diarrhea virus wiping out some 100,000 piglets a week, animal health company VMRD has developed a diagnostic tool that can be used to detect antibody to the virus.

China's HD Bio teams with Marshall U. for cancer R&D

Chinese clinical research outfit HD Biosciences has struck a deal with Marshall University to collaborate on cancer drug development, sharing costs and risks in hopes of commercializing new therapies.

When will Big Pharma get serious about antibiotic R&D?

The 5 most promising antibiotic treatments in the industry's pipeline all have something in common: Not one was developed by Big Pharma.

Ebola outbreak rages on as drug development remains slow

As the death toll from West Africa's Ebola outbreak hits nearly 540--a 60% mortality rate--drug development for the untreatable disease is lagging, largely due to lack of interest from Big Pharma and the relative infrequency of the disease.

DOD awards $40M for wireless implant for memory loss due to brain injury

Soon, there will be a device to cure some forgetfulness if the Department of Defense's four-year grant of up to $40 million succeeds in fostering implants and electronic interfaces that diagnose and treat memory loss due to traumatic brain injury.

Industry Voices: The contributions of immunology translational medicine to clinical pharmaceutical development

Translational medicine, which bridges the science of the emerging preclinical portfolio and the early development space where molecules are studied in humans for the first time, is an important if not essential element of successful pharmaceutical development. 

Regeneron, Sanofi herald a blockbuster contender with groundbreaking study

If you want to understand why Regeneron R&D chief George Yancopolous gets a king's ransom in annual compensation, you need look no further than the Phase IIb data that has just been posted on dupilumab for severe eczema.

Gynesonics aims for $35M for minimally invasive uterine fibroid device

Gynesonics has raised an additional $6 million in its march toward raising a total round of $35.5 million in equity and debt, according to an SEC filing. The additional cash is timely, coming on the heels of its receipt of a European CE mark for and treatment of the first patient with its next-generation VizAblate System in June.

'Unpromising' Allergan drug projects headed for the chopping block--report

Allergan execs have made no secret of the fact that they've been planning to come up with a lean-and-mean game plan designed to prove to investors that they'd be much better off if they spurned Valeant's offer to buy the company and gut its R&D division. Citing sources close to the company,  Bloomberg  is reporting that the cutbacks should include work on its most "unpromising" programs in the pipeline.